Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.
XBP1 is a critical transcriptional activator of the unfolded protein response (UPR), which increases tumor cell survival under prolonged endoplasmic reticulum (ER) stress and hypoxic conditions.This study was designed to evaluate the immunogenicity of heteroclitic XBP1 unspliced (US)184-192(YISPWILAV) and heteroclictic XBP1 spliced (SP)367-375(YLFPQLISV) HLA-A2 peptides, and to characterize the specific activities of XBP1 peptides-specific cytotoxic T lymphocytes (XBP1-CTL) against breast cancer, colon cancer, and pancreatic cancer cells.The XBP1-CTL had upregulated expression of critical T cell markers and displayed HLA-A2-restricted and antigen-specific activities against breast cancer, colon cancer and pancreatic cancer cells. XBP1-CTL were enriched withCD45RO+memory CTL, which showed high expression of critical T cell markers (CD28, ICOS, CD69, CD40L), cell proliferation and antitumor activities as compared to CD45RO-non-memory CTL. The effector memory (EM: CD45RO+CCR7-) subset had the highest level of cell proliferation while the central memory (CM: CD45RO+CCR7+) subset demonstrated enhanced functional activities (CD107a degranulation, IFNγ/IL-2 production) upon recognition of the respective tumor cells. Furthermore, both the EM and CM XBP1-CTL subsets expressed high levels of Th1 transcription regulators Tbet andEomes. The highest frequencies of IFNγ or granzyme B producing cells were detected within CM XBP1-CTL subset that were either Tbet+or Eomes+in responding to the tumor cells.These results demonstrate the immunotherapeutic potential of a cocktail of immunogenic HLA-A2 specific heteroclitic XBP1 US184-192and heteroclictic XBP1 SP367-375peptides to induce CD3+CD8+CTL enriched for CM and EM cells with specific antitumor activities against a variety of solid tumors.
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA.
Jooeun
J
Bae
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA.
Mehmet
M
Samur
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA.
Aditya
A
Munshi
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA.
Teru
T
Hideshima
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA.
Derin
D
Keskin
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA.
Alec
A
Kimmelman
Weill Cornell Medical College ; New York, NY USA.
Ann-Hwee
AH
Lee
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA.
Glen
G
Dranoff
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA.
Kenneth C
KC
Anderson
Dana-Farber Cancer Institute ; Boston, MA USA ; Harvard Medical School ; Boston, MA USA ; VA Boston Healthcare System ; Boston, MA USA.
Nikhil C
NC
Munshi
XBP1; breast / colon / pancreatic cancer; cancer vaccine; heteroclitic peptides